Risk group stratification to predict prognosis in Japanese patients with urothelial carcinoma

• Project/Area Number: 24592393
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Yamaguchi University
• Principal Investigator: SAKANO Shigeru 山口大学, 医学部, 特別医学研究員 (60363107)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
• Keywords: 尿路上皮癌

Outline of Final Research Achievements

Combined ERCC1 and XRCC1 expression may serve as an independent prognostic marker for survival in bladder cancer patients receiving combined trimodality therapy. Prospective studies with a larger sample size are required to confirm these results.
Risk group stratification based on preoperative clinical T stage, voided urine cytology, and WBC counts may be useful for selection of UUT-UC patients for neoadjuvant chemotherapy. Prospective studies with larger numbers of patients and a longer follow-up period are needed to confirm our results.
UTUC with variant histology might be a phenotype of high-grade, locally aggressive advanced tumors rather than of systemic disease. Variant histology may be useful for selection of patients with pT3 and more invasive UTUC for adjuvant therapy. Prospective studies in a larger number of patients with a centralized pathological review are needed to confirm our results.

Research Products

• [Journal Article] Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma (2015)
  • Author(s): Shigeru Sakano, Hideyasu Matsuyama, Yoriaki Kamiryo, Shigeaki Hayashida, Norio Yamamoto, Yoshitaka Kaneda, Takahito Nasu, Yoshikazu Baba, Tomoyuki Shimabukuro, Akinobu Suga, Mitsutaka Yamamoto, Akihiko Aoki, Kimio Takai, Satoru Yoshihiro, Kazuo Oba
  • Journal Title: International Journal of Clinical Oncology Volume: 20 Issue: 2 Pages: 362-368
  • DOI: 10.1007/s10147-014-0721-3
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Risk Group Stratification Based on Preoperative Factors to Predict Survival after Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma (2013)
  • Author(s): Shigeru Sakano, Hideyasu Matsuyama, Yoriaki Kamiryo, Shigeaki Hayashida, Norio Yamamoto, Yoshitaka Kaneda, Takahito Nasu, Osamu Hashimoto, Keiji Joko, Yoshikazu Baba, Tomoyuki Shimabukuro, Akinobu Suga, Mitsutaka Yamamoto, Akihiko Aoki, Kimio Takai, Satoru Yoshihiro, Masafumi Matsumura
  • Journal Title: Annals of Surgical Oncology Volume: 20 Issue: 13 Pages: 4389-4396
  • DOI: 10.1245/s10434-013-3259-0
  • Peer Reviewed
• [Journal Article] ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy (2013)
  • Author(s): SHIGERU SAKANO, SATOSHI OGAWA, YOSHIAKI YAMAMOTO, JUN NISHIJIMA, YOSHIHIRO MIYACHIKA, HIROAKI MATSUMOTO, TAKAHIKO HARA, HIDEYASU MATSUYAMA
  • Journal Title: MOLECULAR AND CLINICAL ONCOLOGY Volume: 1 Issue: 3 Pages: 403-410
  • DOI: 10.3892/mco.2013.85
  • Peer Reviewed
• [Presentation] 日本人上部尿路上皮癌患者において特殊型組織成分が疾患悪性度および予後に及ぼす影響 (2014)
  • Author(s): 坂野 滋，上領頼啓，林田重昭，山本憲男，金田芳孝，那須誉人，馬場良和，島袋智之，須賀昭信，山本光孝，青木明彦，高井公雄，吉弘 悟，大場一生，松山豪泰
  • Organizer: 第52回日本癌治療学会学術集会
  • Place of Presentation: 横浜市（パシフィコ横浜）
  • Year and Date: 2014-08-28 – 2014-08-30
• [Presentation] Risk Group Stratification Based on Preoperative Factors to Predict Survival after Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma (2013)
  • Author(s): Shigeru Sakano, Hideyasu Matsuyama, Yoriaki Kamiryo, Shigeaki Hayashida, Norio Yamamoto, Yoshitaka Kaneda, Takahito Nasu, Keiji Joko, Yoshikazu Baba, Tomoyuki Shimabukuro
  • Organizer: The 33rd Congress of the Societe Internationale d’Urologie (SIU)
  • Place of Presentation: Vancouver, Canada